Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Ricklin

Showing results (21-30 of 135) with videos related to

Pageof 14
Sort By:
American Journal of Hematology|February 9, 2023
Complement-targeted therapeutics: An emerging field enabled by academic drug discoveryChristina Lamers, Daniel Ricklin, John D Lambris
Nature Reviews. Nephrology|May 24, 2016
Complement in disease: a defence system turning offensiveDaniel Ricklin, Edimara S Reis, John D Lambris
Immunological Reviews|October 27, 2016
Protection of host cells by complement regulatorsChristoph Q Schmidt, John D Lambris, Daniel Ricklin
Molecular Immunology|June 4, 2017
Complement in clinical medicine: Clinical trials, case reports and therapy monitoringDaniel Ricklin, Andreas Barratt-Due, Tom Eirik Mollnes
Nature Reviews. Drug Discovery|December 11, 2019
Therapeutic targeting of the complement systemDaniel Ricklin, Dimitrios C Mastellos, John D Lambris
Chimia|July 8, 2021
Therapeutic Peptides as Emerging Options to Restore Misguided Host Defence and Homeostasis: From Teaching to Concept to ClinicOliver Schwardt, Christina Lamers, Clément Bechtler, et al.
Nature Reviews. Microbiology|January 17, 2008
Complement evasion by human pathogensJohn D Lambris, Daniel Ricklin, Brian V Geisbrecht
Nature Reviews. Drug Discovery|July 21, 2019
Clinical promise of next-generation complement therapeuticsDimitrios C Mastellos, Daniel Ricklin, John D Lambris
Nature Medicine|September 11, 2012
A sweet spot to control complement-induced inflammationDaniel Ricklin, Edimara S Reis, John D Lambris
Clinical Immunology (Orlando, Fla.)|June 20, 2021
From discovery to approval: A brief history of the compstatin family of complement C3 inhibitorsDimitrios C Mastellos, Daniel Ricklin, Georgia Sfyroera, et al.
Pageof 14

Showing results (21-30 of 135) with videos related to

Sort By:
Pageof 14
American Journal of Hematology|February 9, 2023
Complement-targeted therapeutics: An emerging field enabled by academic drug discoveryChristina Lamers, Daniel Ricklin, John D Lambris
Nature Reviews. Nephrology|May 24, 2016
Complement in disease: a defence system turning offensiveDaniel Ricklin, Edimara S Reis, John D Lambris
Immunological Reviews|October 27, 2016
Protection of host cells by complement regulatorsChristoph Q Schmidt, John D Lambris, Daniel Ricklin
Molecular Immunology|June 4, 2017
Complement in clinical medicine: Clinical trials, case reports and therapy monitoringDaniel Ricklin, Andreas Barratt-Due, Tom Eirik Mollnes
Nature Reviews. Drug Discovery|December 11, 2019
Therapeutic targeting of the complement systemDaniel Ricklin, Dimitrios C Mastellos, John D Lambris
Chimia|July 8, 2021
Therapeutic Peptides as Emerging Options to Restore Misguided Host Defence and Homeostasis: From Teaching to Concept to ClinicOliver Schwardt, Christina Lamers, Clément Bechtler, et al.
Nature Reviews. Microbiology|January 17, 2008
Complement evasion by human pathogensJohn D Lambris, Daniel Ricklin, Brian V Geisbrecht
Nature Reviews. Drug Discovery|July 21, 2019
Clinical promise of next-generation complement therapeuticsDimitrios C Mastellos, Daniel Ricklin, John D Lambris
Nature Medicine|September 11, 2012
A sweet spot to control complement-induced inflammationDaniel Ricklin, Edimara S Reis, John D Lambris
Clinical Immunology (Orlando, Fla.)|June 20, 2021
From discovery to approval: A brief history of the compstatin family of complement C3 inhibitorsDimitrios C Mastellos, Daniel Ricklin, Georgia Sfyroera, et al.
Pageof 14